- Home
- BANX vs CCCC Comparison
BANX vs CCCC Comparison
Compare BANX & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BANX
- CCCC
- Stock Information
- Founded
- BANX 2013
- CCCC 2015
- Country
- BANX United States
- CCCC United States
- Employees
- BANX N/A
- CCCC N/A
- Industry
- BANX Trusts Except Educational Religious and Charitable
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- BANX Finance
- CCCC Health Care
- Exchange
- BANX Nasdaq
- CCCC Nasdaq
- Market Cap
- BANX 143.2M
- CCCC 115.0M
- IPO Year
- BANX N/A
- CCCC 2020
- Fundamental
- Price
- BANX $19.96
- CCCC $1.47
- Analyst Decision
- BANX
- CCCC Buy
- Analyst Count
- BANX 0
- CCCC 4
- Target Price
- BANX N/A
- CCCC $12.50
- AVG Volume (30 Days)
- BANX 16.4K
- CCCC 1.3M
- Earning Date
- BANX 06-13-2025
- CCCC 05-07-2025
- Dividend Yield
- BANX 10.49%
- CCCC N/A
- EPS Growth
- BANX N/A
- CCCC N/A
- EPS
- BANX 2.35
- CCCC N/A
- Revenue
- BANX $29,467,794.00
- CCCC $39,783,000.00
- Revenue This Year
- BANX N/A
- CCCC N/A
- Revenue Next Year
- BANX N/A
- CCCC $36.31
- P/E Ratio
- BANX $8.61
- CCCC N/A
- Revenue Growth
- BANX 2.73
- CCCC 98.56
- 52 Week Low
- BANX $17.91
- CCCC $1.09
- 52 Week High
- BANX $21.67
- CCCC $7.66
- Technical
- Relative Strength Index (RSI)
- BANX 47.62
- CCCC 44.60
- Support Level
- BANX $19.93
- CCCC $1.42
- Resistance Level
- BANX $20.28
- CCCC $1.69
- Average True Range (ATR)
- BANX 0.42
- CCCC 0.16
- MACD
- BANX 0.04
- CCCC 0.03
- Stochastic Oscillator
- BANX 26.00
- CCCC 27.27
About BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds, and others.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.